Last updated: February 28, 2026
What is the current excipient landscape for sacubitril and valsartan formulations?
The fixed-dose combination (FDC) of sacubitril and valsartan, marketed as Entresto by Novartis, employs specific excipients to optimize stability, bioavailability, and patient compliance. The composition typically includes diluents, binders, disintegrants, lubricants, and coating agents. In commercial formulations, excipients are selected based on compatibility with active pharmaceutical ingredients (APIs), manufacturing processes, and regulatory standards.
Common excipients in sacubitril/valsartan formulations:
- Lactose monohydrate: filler and diluent; enhances compressibility
- Microcrystalline cellulose: binder and filler
- Hydroxypropyl methylcellulose (HPMC): sustained-release matrix component (if applicable)
- Croscarmellose sodium: disintegrant
- Magnesium stearate: lubricant
In capsules, gelatin or hydroxypropyl methylcellulose (HPMC) shells are used. Coatings may involve polymers like ethylcellulose or film-forming agents.
What are the strategic considerations for excipient selection?
Regulatory and stability considerations
Excipients must comply with pharmacopeial standards and demonstrate compatibility with APIs. Stability studies inform choice; for example, lactose-based excipients are avoided with moisture-sensitive APIs, but are standard in many formulations due to cost-effectiveness.
Manufacturing scalability and cost
High-volume production favors excipients that are cost-efficient, readily available, and compatible with existing equipment. Lactose and microcrystalline cellulose are favored due to their established supply chains.
Patient compliance
Taste-masking, disintegration time, and tablet size influence excipient selection. For instance, disintegrants like croscarmellose sodium reduce tablet disintegration time, improving onset of action.
Novel excipients and technology adoption
Emerging excipients such as biodegradable polymers or engineered disintegrants present opportunities to improve drug release profiles. Additionally, switching to HPMC-based coatings enhances plant-based compliance trends, especially for vegetarian or vegan formulations.
What are the commercial opportunities stemming from excipient innovation?
Development of advanced formulations
- Extended-release (ER) or sustained-release (SR) versions: utilizing polymers like HPMC or ethylcellulose to increase dosing intervals, potentially reducing pill burden.
- Taste-masked formulations: employing novel coating agents or ion-exchange resins to enhance palatability.
- Oral dispersible tablets (ODTs): incorporating superdisintegrants and excipients that allow rapid disintegration in the mouth, improving adherence among elderly or pediatric populations.
Platform technology licensing
Proprietary excipient-based platforms—such as multiparticulate systems or lipid-based carriers—offer licensing potential for generic manufacturers seeking to differentiate products.
Biosimilar and formulation optimization opportunities
While biosimilars are less relevant for small molecules, optimization of excipient profiles for generics can provide cost advantages or improved performance, attracting market share.
Packaging and delivery innovations
Encapsulating excipient systems compatible with novel delivery methods (e.g., film-coated minitablets, controlled-release patches) can access emerging niches in hypertension management.
What regulatory trends influence excipient strategies?
- EMA and FDA guidance emphasize excipient safety, especially in pediatric and geriatric populations.
- Increasing focus on excipients' environmental impact and sustainability influences selection up or down.
- The global move towards plant-based and gluten-free excipients expands opportunities for excipient sourcing.
What are the principal competitive dynamics?
- Major pharmaceutical players such as Novartis, Teva, and Sandoz control the marketed formulations and established excipient profiles.
- Innovation in excipient usage or new delivery platforms can yield patent extensions or product differentiation.
- Contract manufacturing organizations (CMOs) are investing in advanced excipient formulation expertise, consolidating supply chains.
Summary table: Excipient components and applications
| Excipient Type |
Application/Function |
Key Considerations |
| Fillers/Diluents |
Volume expansion, stability |
Cost, regulatory approval |
| Binders |
Tablet cohesion |
Compatibility with APIs, manufacturing process |
| Disintegrants |
Fast tablet breakup |
Disintegration time, patient adherence |
| Lubricants |
Ease of tablet compression |
Impact on dissolution, manufacturing equipment |
| Coatings |
Taste masking, controlled release |
Material source, regulatory status |
Key Opportunities
- Adoption of plant-based and biodegradable excipients
- Development of extended-release systems
- Formulation improvements for pediatric and elderly populations
- Licensing proprietary excipient technologies for differentiation
Key takeaways
- Excipient selection influences formulation stability, bioavailability, and patient compliance.
- Cost, regulatory compliance, and compatibility drive current excipient choices in sacubitril and valsartan products.
- Innovation in excipient technology enables formulation differentiation, extended patent life, and market expansion.
- Emerging trends favor plant-based, sustainable, and versatile excipients suited for novel delivery platforms.
- Strategic partnerships and licensing in excipient technology can unlock competitive advantages.
FAQs
-
What are the main excipients used in sacubitril/valsartan tablets?
Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and possibly HPMC for coatings or controlled-release matrices.
-
Can excipient innovation extend the patent life of sacubitril/valsartan formulations?
Yes. Incorporating novel excipients or delivery systems like extended-release matrices can serve as inventive steps, potentially securing patent protection.
-
What regulatory challenges exist for excipient changes in sacubitritr and valsartan products?
Changes require compatibility and stability data with APIs and must meet pharmacopeial standards. Regulatory authorities may require bioequivalence studies if excipient modifications affect bioavailability.
-
How does excipient choice affect marketability in different regions?
Regional standards and preferences influence excipient selection. For example, vegetarian or vegan excipients are preferred in Europe, while cost-effective lactose-based excipients dominate other markets.
-
Are there environmental considerations influencing excipient selection?
Yes. Increased focus on sustainability favors biodegradable and plant-based excipients, reducing environmental impact and aligning with regulatory trends.
References
[1] U.S. Food and Drug Administration. (2021). Guidelines on Excipients in Drug Products.
[2] European Medicines Agency. (2022). Reflection Paper on the Use of Excipients in the Formulation of Pharmacological Products.
[3] Novartis. (2015). Entresto (Sacubitril/Valsartan) Prescribing Information.
[4] FDA. (2020). Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients.
[5] European Pharmacopoeia. (2023). Excipients Monographs and Standards.
